Recce Pharmaceuticals Ltd. (AU:RCE)
ASX:RCE
RCE Stock Chart & Stats
AU$0.41
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.41
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.28 - AU$0.73
Previous CloseN/A
Volume21.12K
Average Volume (3M)154.69K
Market Cap
AU$134.47M
Enterprise ValueAU$145.37M
Total Cash (Recent Filing)AU$602.99K
Total Debt (Recent Filing)AU$11.26M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding289,183,400
10 Day Avg. Volume112,630
30 Day Avg. Volume154,688
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)-22.52
Price to Sales (P/S)9.15
P/FCF Ratio-3.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GrowthSustained FCF growth (51.97%) signals improving cash conversion despite losses. Over 2–6 months this can materially extend clinical program runway, reduce immediate reliance on dilutive capital, and give management flexibility to prioritize trials or partnerships.
Positive ROE Indicates Operational EfficiencyA positive ROE (7.02%) suggests the company is extracting returns from its equity base despite headwinds. That operational efficiency can support disciplined capital allocation, improving the chances that R&D spending yields valuable clinical readouts or partner interest over the medium term.
Platform Targeting Drug‑resistant InfectionsRecce’s platform addresses structural, long-term unmet need of antibiotic resistance. A platform approach enables multiple clinical candidates and partnership/licensing options, supporting durable strategic value creation if clinical validation progresses over the coming months.
Bears Say
Declining Revenue And Deeply Negative MarginsMaterial revenue decline and very negative margins reflect weak commercial or early-stage monetization. Persisting losses at this magnitude will require recurring funding, undermining sustainability and making it harder to scale programs or retain negotiating leverage with partners over the medium term.
Negative Equity And High LeverageNegative equity and a highly negative debt-to-equity ratio indicate structural balance sheet weakness. This elevates insolvency and refinancing risk, reduces access to traditional financing, and increases dependency on dilutive capital or partnerships to fund ongoing clinical development.
Insufficient Operating Cash GenerationNegative operating cash flow relative to net losses shows core operations do not produce sustainable cash. Over months this forces reliance on external financing, which can drive dilution, constrain strategic choices, and delay development milestones if capital markets or partners are inaccessible.
Recce Pharmaceuticals Ltd. News
RCE FAQ
What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?
Recce Pharmaceuticals Ltd. lowest share price was AU$0.28 and its highest was AU$0.73 in the past 12 months.
What is Recce Pharmaceuticals Ltd.’s market cap?
Recce Pharmaceuticals Ltd.’s market cap is AU$134.47M.
When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?
Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 144 days.
How were Recce Pharmaceuticals Ltd.’s earnings last quarter?
Recce Pharmaceuticals Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.057 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.057.
Is Recce Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Recce Pharmaceuticals Ltd. pay dividends?
Recce Pharmaceuticals Ltd. does not currently pay dividends.
What is Recce Pharmaceuticals Ltd.’s EPS estimate?
Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recce Pharmaceuticals Ltd. have?
Recce Pharmaceuticals Ltd. has 289,183,400 shares outstanding.
What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?
Recce Pharmaceuticals Ltd. reported an EPS of -AU$0.057 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.917%.
Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:RCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recce Pharmaceuticals Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.63%
12-Months-Change
Fundamentals
Return on Equity
279.21%
Trailing 12-Months
Asset Growth
-51.48%
Trailing 12-Months
Company Description
Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. (RCE) is a biotechnology company focused on the development and commercialization of innovative anti-infective therapies. The company specializes in creating synthetic polymers to combat serious infections, particularly those caused by antibiotic-resistant bacteria. Recce's lead product candidate, RECCE 327, is designed to treat a range of infections, including sepsis, and is positioned to address the growing global health challenge of antibiotic resistance.
Technical Analysis
Amplia Therapeutics
―
Imugene
―
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---